Vyepti Approval History
Reviewed by J.Stewart BPharm Last updated on Mar 22, 2020.
Vyepti (eptinezumab-jjmr) is a calcitonin gene-related peptide antagonist indicated for the prevention of migraine in adults.
- Vyepti is administered as an intravenous infusion over approximately 30 minutes, every 3 months.
- Vyepti may cause serious hypersensitivity reactions. Patients should contact their healthcare provider immediately if they experience signs or symptoms of a hypersensitivity reaction such as angioedema, urticaria, facial flushing, or rash.
- Common side effects include nasopharyngitis and hypersensitivity reactions. Most of the hypersensitivity reactions that occurred in clinical trials were not serious, but often led to discontinuation, or required treatment.
Development History and FDA Approval Process for Vyepti
|Feb 22, 2020||FDA Approves Vyepti (eptinezumab-jjmr) Intravenous Injection for the Preventive Treatment of Migraine|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.